ABSTRACT Inhalation of sodium metabisulphite is thought to induce bronchoconstriction by release of sulphur dioxide. We sought to establish the reproducibility of the airway response to inhaled sodium metabisulphite given in increasing doubling concentrations (0 3 to 160 mg/ml) to 13 asthmatic and five atopic non-asthmatic subjects and the contribution of cholinergic mechanisms to this response. In 15 of the 18 subjects bronchoconstriction was sufficient to allow calculation of the dose ofmetabisulphite causing a 20% reduction in the forced expiratory volume in one second (FEVy) from baseline values (PD20 metabisulphite). The 95% confidence limit for the difference between this and a second PD20 metabisulphite determined 2-14 days later was 2 5 doubling doses. The difference between repeat PD20 metabisulphite measurements was unrelated to the number of days between challenges or change in baseline FEVy. Ten subjects returned for a third study 3-120 days after the second challenge; variability in PD20 metabisulphite did not differ from that seen between the first and second challenges. PD20 methacholine was determined between the two metabisulphite challenges and found to correlate with PD20 metabisulphite (r = 0-71). Inhaled ipratropium bromide 200 jug given in a randomised, placebo controlled, crossover study to 10 subjects increased PD20 methacholine 42 fold but had no significant effect on the response to metabisulphite. A single inhalation of the PD20 metabisulphite in five subjects induced maximal bronchoconstriction 2-3 minutes after inhalation, with a plateau in FEV, lasting a further four minutes before recovery. A further single inhalation of the same PD20 dose 43 minutes later produced a 27% (SEM 4%) smaller fall in FEV, than the first inhalation. These results show that metabisulphite PD20 values measured over days and weeks show similar reproducibility to those reported for histamine inhalation and that PD20 metabisulphite correlates with methacholine responsiveness. Most of the bronchoconstriction is not inhibited by antimuscarinic agents; the underlying mechanisms require further investigation.
Introduction
Inhaled aerosols of the preservative agent sodium metabisulphite seem to cause bronchoconstriction in a large proportion of asthmatic subjects: in one study of 0 5 and 5 mg/ml aerosols six out of eight unselected asthmatic patients showed bronchoconstriction.' This effect is attributed to sulphur dioxide generated by the solutions. Oral ingestion of metabisulphite can cause severe and even life threatening asthma,23 but this is rare in comparison with the response to inhaled aerosols. Inhaled sulphur dioxide gas and metabi-sulphite aerosol may have a common mode of action as bronchoconstriction caused by both agents is inhibited by inhaled cromoglycate and, in some studies at least, by anticholinergic drugs.45 The mechanism whereby sulphur dioxide and metabisulphite cause bronchoconstriction, however, remains unknown.
Expensive measuring equipment is needed to administer sulphur dioxide safely to asthmatic patients. In contrast,. the methods required to administer metabisulphite aerosols are cheap, simple, and similar to methods already used in methacholine and histamine challenges. 5 We report the reproducibility of cumulative dose-responses to inhaled metabisulphite in a group of atopic subjects with and without asthma over a few days and weeks. We compared the responses to metabisulphite with those to methacholine and 1009 1010 the effect of pretreatment with inhaled ipratropium bromide on the response to inhaled metabisulphite. We ascertained the time course of bronchoconstriction after a single dose of inhaled metabisulphite and sought to establish whether short term tachyphylaxis occurred with a further single inhalation.
Methods

SUBJECTS
Thirteen asthmatic (nine men, four women) and five non-asthmatic subjects were initially assessed for inclusion in the study. All subjects were atopic to common environmental allergens based on positive results to skin prick tests and were unaware of any previous adverse reactions to sulphites. They were all non-smokers.
All subjects gave informed consent to a protocol approved by the Brompton Hospital Ethics Committee. Subjects had not had an-upper respiratory tract infection for four weeks before the study. They abstained from using sympathomimetic and anticholinergic drugs and sodium cromoglycate for eight hours and from taking drugs or drinks containing xanthines for 24 hours before each day's testing.
One non-asthmatic and two asthmatic subjects failed to show a reduction in forced expiratory volume in one second (FEVY) of 20% after the highest dose of metabisulphite. The remaining 15 PD20 metabisulphite was determined in the 15 subjects at the same time of day on two non-consecutive days, six (range 2-14) days apart. A methacholine challenge was also performed. On a separate day between the first two metabisulphite challenges, consecutive doubling concentrations of methacholine (Sigma, Poole) (0 06-128 mg/ml in normal saline) were administered at four minute intervals to all subjects with the same nebuliser-dosimeter system as in the metabisulphite challenge. PD20 methacholine (pmol) was determined as for PD20 metabisulphite. Seven asthmatic and three atopic non-asthmatic subjects (aged 28 (2) years, range 20-4) underwent a third metabisulphite challenge 32 (11) Characterisation ofbronchoconstrictor responses to sodium metabisulphite aerosol in atopic subjects ute for five minutes and every five minutes thereafter until it had returned to within 5% of the baseline value; this took 43 (9) minutes. To determine whether there was a tachyphylactic response to the bronchoconstrictor effect of inhaled metabisulphite a further identical dose of metabisulphite was then inhaled and FEVY measured every minute until maximum bronchoconstriction had again occurred.
ANALYSIS
Data on PD20 metabisulphite and PD20 methacholine were log transformed for statistical analysis and expressed as geometric means (geometric standard errors). All other data are expressed as means (standard errors). Paired comparisons of FEV, and log PD20 data were made with Student's paired t test. All linear correlations were made with the least squares method. PD20 metabisulphite measurements on all three open challenge days were compared with PD20 metabisulphite on the placebo challenge day with analysis of variance for repeated measures. 6 The presence and duration ofthe plateau in the time course of bronchoconstriction by metabisulphite were established also with analysis of variance for repeated measures.
Results
Metabisulphite challenge was as simple to perform as challenge with methacholine. All subjects noticed mild irritation and cough when inhaling concentrations of metabisulphite greater than 20 mg/ml. Challenges with both metabisulphite and methacholine took 30 to 45 minutes to complete, and the induced bronchoconstriction was quickly reversed with an inhaled sympathomimetic agonist. None of the subjects reported irritation or wheezing in the hours or days after challenge.
All but two asthmatic subjects and one non-asthmatic subject showed a dose dependent decrease in FEV, with metabisulphite challenge, achieving a 20% reduction in FEV, after inhaling up to 160 mg/ml of metabisulphite. Inhalation of higher concentrations was not possible because of cough and irritation.
REPRODUCIBILITY OF METABISULPHITE RESPONSES
FEV, values before the first metabisulphite challenge (3 31 (0 25) litres) did not differ significantly from those before the second (3 30 (0-26) litres). The geometric mean PD20 for the first and second test, 1-31 and 1 79 umol, did not differ significantly. The absolute mean difference between the first and second PD20 metabisulphite measurements was 0 9 (0-2) doubling dose intervals; the 95% confidence limit for the difference between the two PD20 measurements was 2-5 doubling dose intervals. There was a 32 fold to 64 fold range of sensitivity to inhaled metabisulphite between subjects, non-asthmatic subjects being less sensitive to metabisulphite than those with asthma ( fig  1) The range of sensitivity to methacholine between subjects (0 01 to 2A48) was 256 fold, and greater than the range for metabisulphite (0 3-7 04). There was, however, a significant linear correlation between the mean of two PD20 metabisulphite measurements and PD20 methacholine (r = 0-714, p < 0 05) in the 15 subjects (fig 2) . The molar potency of metabisulphite was about six times less than that of methacholine.
EFFECT OF IPRATROPIUM BROMIDE ON PD20 METABISULPHITE AND PD20 METHACHOLINE
There was no significant difference in baseline FEV, 17-8 imol) . Pretreatment with ipratropium caused no significant change in PD20 metabisulphite compared with placebo (geometric mean 2-3 (1-4) imol after placebo, [2] [3] [4] [5] [6] (1-5) imol after ipratropium).
TIME COURSE AND TACHYPHYLAXIS AFTER SINGLE DOSE INHALATIONS
The time course of response to a single inhalation of metabisulphite on two occasions 43 (9) minutes apart, are shown for each subject in figure 3 . Maximum bronchoconstriction occurred two minutes (range 1-3) after inhalation. Analysis of variance for repeated measures6 showed no significant change in FEV, between three and seven minutes, with significant recovery occurring thereafter. The second response was less than the first in all subjects, the lowest FEV, being 2-47 (0-5) litres after the first inhalation and 2-62 (0-5) litres after the second (p < 0-05). When expressed as a percentage of baseline FEV, the second response was 27% (4%) less than the first response. Time after challenge (min) 4 Using a method similar to our own for a 35% reduction in specific airways conductance, Dixon and Ind found a small (1 4 doubling dose interval) inhibition of the response to inhaled metabisulphite in atopic subjects given inhaled oxitropium. 5 The greater degree of bronchoconstriction in this study (reduction in FEV, of 20%) may explain why we were unable to achieve any inhibition with ipratropium bromide. The lack of effect cannot be attributed to an insufficient dose ofipratroprium, as 100 ,ug is as effective as 200 ,g or the addition of 2 mg of atropine2' in inhibiting sulphur dioxide induced responses and the 200 ,ug dose was effective in reducing the response to methacholine challenge.
The small or variable response to anticholinergic agents suggests that most of the response to inhaled metabisulphite is not mediated through parasympathetic nervous pathways. Metabisulphite or sulphur dioxide may cause the release of secondary mediators, though the potent histamine receptor antagonist terfenadine provides no protection.5 Nedocromil sodium522 and sodium cromoglycate23 are, however, potent inhibitors of bronchoconstriction induced by metabisulphite and sulphur dioxide, presumably by a mechanism unrelated to inhibition of histamine release from mast cells. Bradykinin shows a similar pattern of activity being inhibited by cromoglycate24 but little affected by antihistamine pretreatment.25 As cromoglycate inhibits afferent nerve transmission,2627 the effects of metabisulphite and bradykinin may be mediated through non-cholinergic excitatory neural pathways.28 Metabisulphite might also exert its effects by causing the release of bradykinin. Finally, although the mechanisms underlying bronchoconstriction induced by sulphur dioxide and metabisulphite are likely to be similar, different distributions of sulphur dioxide gas and metabisulphite aerosol within the lung may be another reason why responses to the two agents differ.
Irrespective of the mechanism underlying sulphite induced bronchoconstriction, challenge with increasing doubling doses of inhaled sodium metabisulphite aerosols is a simple and reproducible tool for studying bronchoconstriction mediated by non-cholinergic pathways in asthmatic subjects.
